Login to Your Account



ASCO 2012

T-DM1 Slows Breast Cancer, with Fewer Side Effects

By Anette Breindl
Science Editor

Tuesday, June 5, 2012
CHICAGO – Roche AG subsidiary Genentech Inc. and partner ImmunoGen Inc. had what looks to be another winner at Sunday's plenary session of the American Society of Clinical Oncology (ASCO) annual meeting.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription